Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.21 - $5.63 $546 - $14,638
-2,600 Reduced 10.2%
22,900 $5,000
Q3 2022

Nov 14, 2022

SELL
$0.46 - $6.75 $4,416 - $64,800
-9,600 Reduced 27.35%
25,500 $10,000
Q2 2022

Aug 15, 2022

SELL
$0.27 - $0.61 $35,532 - $80,276
-131,600 Reduced 78.94%
35,100 $18,000
Q1 2022

May 16, 2022

SELL
$0.5 - $0.88 $263,000 - $462,880
-526,000 Reduced 75.93%
166,700 $98,000
Q4 2021

Feb 14, 2022

SELL
$0.58 - $1.09 $242,555 - $455,838
-418,200 Reduced 37.65%
692,700 $403,000
Q3 2021

Nov 15, 2021

BUY
$0.93 - $1.18 $523,218 - $663,868
562,600 Added 102.61%
1,110,900 $1.26 Million
Q2 2021

Aug 16, 2021

BUY
$1.19 - $2.06 $391,272 - $677,328
328,800 Added 149.79%
548,300 $652,000
Q1 2021

May 17, 2021

BUY
$1.62 - $3.05 $355,590 - $669,475
219,500 New
219,500 $452,000

Others Institutions Holding ECOR

About electroCore, Inc.


  • Ticker ECOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 71,176,896
  • Market Cap $1.09B
  • Description
  • electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults....
More about ECOR
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.